Results 221 to 230 of about 4,660,604 (252)

CASTOR1 regulates humoral immune responses and contributes to the pathogenesis of systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda   +5 more
wiley   +1 more source

Single‐cell RNA sequencing of peripheral blood defines two immunological subtypes of Sjögren's disease distinguished by anti‐SSA antibodies and aberrant B cell populations

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Sjögren's disease (SjD) is a heterogeneous autoimmune disorder characterized by substantial clinical and molecular diversity. This heterogeneity raises key questions regarding the existence of distinct pathogenic mechanisms underlying disease subtypes.
Geoffrey Urbanski   +15 more
wiley   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

open access: yesBiotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu   +3 more
wiley   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

Atomically precise metal cluster enzymes for pathological tissue regeneration

open access: yesBMEMat, EarlyView.
Schematic illustration of atomically precise metal cluster enzymes (MCEs) for pathological tissue regeneration. Atomically precise MCEs can modulate biological processes, such as attenuation of inflammatory responses, eradication of bacterial pathogens, regulation of angiogenesis, and promotion of cell development.
Ziqiang Xiong   +11 more
wiley   +1 more source

Pt‐TiO2 mesoporous nanosystem co‐delivering phlorezin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

open access: yesBMEMat, EarlyView.
Abstract Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO2 nanoparticles for the co‐delivery of Phlorezin, presenting a novel approach for HCC treatment through sonodynamic ...
Kairui Liu   +13 more
wiley   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

open access: yesBMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning   +10 more
wiley   +1 more source

Integrated spherical nucleic acid nanoreactor mobilizes targeted PD‐L1 proteolysis and cuproptosis for robust breast cancer immunotherapy

open access: yesBMEMat, EarlyView.
This study provides an integrated spherical nucleic acid nanoreactor (denoted as AMCuD) for targeted PD‐L1 degradation and chemo‐dynamically enhanced cuproptosis to synergically elicit robust immunotherapy against the triple‐negative breast cancer (TNBC) growth, recurrence and metastasis.
Ningxi Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy